Hemogenyx Pharmaceuticals Plc
HEMO.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | – | £14 | £16 | £27 |
| - Cash | £0 | £0 | £2 | £1 |
| + Debt | £2 | £3 | £3 | £3 |
| Enterprise Value | – | £17 | £17 | £29 |
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | – | – | – | – |
| Gross Profit | -£0 | -£0 | -£1 | -£0 |
| % Margin | – | – | – | – |
| EBITDA | -£5 | -£2 | -£5 | -£2 |
| % Margin | – | – | – | – |
| Net Income | -£5 | -£3 | -£0 | -£2 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.42 | -0.8 | -0.001 | -0.81 |
| % Growth | -77.5% | -88,788.9% | 99.9% | – |
| Operating Cash Flow | -£4 | -£2 | -£0 | -£3 |
| Capital Expenditures | -£0 | -£0 | £0 | -£0 |
| Free Cash Flow | -£4 | -£2 | -£0 | -£3 |